Table 1 Clinical trials of therapeutic agents registered in the NCT and NMPA platforms
From: Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
Platform | Type of Agents | Agent | Organization | NCT Number | Status | Conditions | Phase | Enrollment | Start Dates |
|---|---|---|---|---|---|---|---|---|---|
Clinical trials registered in the NMPA platform | mAb | Zolbetuximab (IMAB362) | Astellas Pharma | CTR20190258 | Recruiting | CLDN18.2+, HER2- advanced/metastatic GC | III | 550 | 4/19/2019 |
mAb | Zolbetuximab (IMAB362) | Astellas Pharma | CTR20190261 | Recruiting | CLDN18.2+, HER2- advanced/metastatic GC | III | 500 | 4/19/2019 | |
mAb | AB011 | CARsgen Therapeutics | CTR20200515 | Recruiting | CLDN18.2+ solid tumors | I | 103 | 5/21/2020 | |
mAb | TST001 | Mabspace Biosciences | CTR20201281 | Recruiting | Advanced/metastatic solid tumors | I | 210 | 8/3/2020 | |
mAb | MIL93 | Mabworks Biotech | CTR20202436 | Recruiting | Advanced/metastatic solid tumors | I | 228 | 12/2/2020 | |
mAb | M108 | FutureGen Biopharm | CTR20210508 | Recruiting | Advanced solid tumor, GC, ST | I | 160 | 3/31/2021 | |
mAb | LM-102 | LaNova Medicines | CTR20211708 | Recruiting | CLDN18.2+ solid tumors | I | 265 | 7/22/2021 | |
mAb | LM-302 | LaNova Medicines | CTR20212820 | Recruiting | Solid tumors | I | 128 | 11/17/2021 | |
mAb | NBL-015 | NovaRock Biotherapeutics | CTR20213166 | Active, not recruiting | PC, ST | I | N/A | 12/8/2021 | |
Bispecific antibody | Q-1802 | Qurebio | CTR20210800 | Recruiting | Advanced/metastatic solid tumors | I | 66 | 4/14/2021 | |
CAR-T cell | CT041 | Shanghai Keji Pharma | CTR20201940 | Recruiting | CLDN18.2+, HER2- advanced/metastatic GC | II | 102 | 10/9/2020 | |
ADC | ASKB589 | Jiangsu Aosaikang | CTR20202121 | Recruiting | Advanced solid tumors | II | 214 | 10/29/2020 | |
ADC | CMG901 | Keymed Biosciences | CTR20202456 | Recruiting | Advanced/metastatic solid tumors | I | 122 | 12/9/2020 | |
ADC | SYSA1801 | CSPC Pharma | CTR20211879 | Recruiting | Advanced/metastatic solid tumors | I | 272 | 6/16/2021 | |
ADC | RC118 | RemeGen | CTR20212857 | Recruiting | Solid tumors | I/IIa | 135 | 11/29/2021 | |
Clinical trials registered in the NCT platform | mAb | Zolbetuximab (IMAB362) | Astellas Pharma | NCT03504397 | Recruiting | Advanced unresectable GEJ cancer or GC | III | 550 | 6/21/2018 |
mAb | Zolbetuximab (IMAB362) | Astellas Pharma | NCT03505320 | Active, not recruiting | Advanced unresectable GEJ cancer or GC | II | 116 | 2018-0-69-29 | |
mAb | Zolbetuximab (IMAB362) | Astellas Pharma | NCT03653507 | Recruiting | Advanced unresectable GEJ cancer or GC | III | 500 | 26-Sep-18 | |
mAb | Zolbetuximab (IMAB362) | Astellas Pharma | NCT03816163 | Recruiting | Metastatic PC | II | 369 | 15-Mar-19 | |
mAb | AB011 | CARsgen Therapeutics | NCT04400383 | Recruiting | Solid tumor, GC, PC | I | 103 | 4-Jun-20 | |
mAb | TST001 | Mabspace Biosciences | NCT04495296 | Recruiting | Advanced cancers | I | 210 | 13-Aug-20 | |
mAb | ASKB589 | Jiangsu Aosaikang Pharmaceutical | NCT04632108 | Active, not recruiting | PC, solid tumors, ST | I, II | N/A | 28-Jan-21 | |
mAb | BNT141–01 | BioNTech SE | NCT04683939 | Recruiting | Solid tumors | I, II | 48 | Dec-21 | |
mAb | LM102 | LaNova Medicines | NCT04735796 | Recruiting | Advanced solid tumors | I | 30 | 16-Jun-21 | |
mAb | LS-CLDN18.2001 | Mabspace Biosciences | NCT04989010 | Active, not recruiting | Solid tumors | I | 20 | 1-Aug-21 | |
mAb | LM-102 | LaNova Medicines | NCT05008445 | Recruiting | Advanced solid tumors | I, II | 265 | 6-Oct-21 | |
mAb | ZL-1211 | Zai Biopharmaceutical. | NCT05065710 | Recruiting | Advanced solid tumors | I, II | 162 | Oct-21 | |
mAb | FL-301 | Nanjing Kaedi Biotech, Flame Biosciences | NCT05181865 | Active, not recruiting | Solid tumors | I, II | 115 | Feb-22 | |
Bispecific antibody | AMG-910 | Amgen | NCT04260191 | Active, not recruiting | GC or GEJ adenocarcinoma | I | 16 | 29-Jun-20 | |
Bispecific antibody | Q-1802 | Qurebio | NCT04856150 | Recruiting | Esophageal tumors, PC, solid tumors, ST | I | 66 | 4/14/2021 | |
CAR-T cell | CT041 | CARsgen Therapeutics | NCT03159819 | Recruiting | Advanced GC, PC | I | 24 | 1-Apr-17 | |
CAR-T cell | Engineered CAR-T cells | Hunan Zhaotai Yongren Medical | NCT03198052 | Recruiting | Lung cancer | I | 30 | 1-Jul-17 | |
CAR-T cell | CT041 | CARsgen Therapeutics | NCT03874897 | Recruiting | Advanced solid tumors | I | 123 | 26-Mar-19 | |
CAR-T cell | CT041 | CARsgen Therapeutics | NCT04404595 | Recruiting | GC, PC | I | 30 | 23-Oct-20 | |
CAR-T cell | LCARC18S | Nanjing Legend Biotech Co. | NCT04467853 | Recruiting | GC | I | 34 | 21-Sep-20 | |
CAR-T cell | CT041 | CARsgen Therapeutics | NCT04581473 | Recruiting | GC, PC, GEJ adenocarcinoma | I, II | 102 | 23-Oct-20 | |
CAR-T cell | LY011 | Shanghai Longyao Biotechnology | NCT04966143 | Recruiting | PC | I | 30 | 1-Aug-21 | |
CAR-T cell | LY011 | Shanghai Longyao Biotechnology | NCT04977193 | Recruiting | Advanced gastric adenocarcinoma | I | 18 | 1-Nov-21 | |
ADC | CMG901 | KeyMed Biosciences | NCT04805307 | Recruiting | Advanced solid tumors, ST | I | 162/122 | 12/24/2020 | |
ADC | 124I-18B10 (10 L) PET/CT | Transcenta | NCT04883970 | Recruiting | GC | I | 15 | 13-May-21 | |
ADC | SYSA1801 | CSPC ZhongQi Pharma | NCT05009966 | Recruiting | Advanced solid tumors, GC, GEJ cancer, PC | I | 272 | 16-Sep-21 | |
ADC | CPO102-US-1001 | Conjupro Biotherapeutics | NCT05043987 | Active, not recruiting | PC, GC | I | 72 | 15-Feb-22 | |
ADC | LM-302 | LaNova Medicines | NCT05161390 | Active, not recruiting | Advanced solid tumors | I, II | 128 | 30-Dec-21 |